drugset / Trial / NCT06111326
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Phase Ib: Dose exploration: To assess the safety, tolerability, and determine the recommended Phase 2 dose (RP2D) of BC3402 in combination with durvalumab in subjects with advanced hepatocellular carcinoma (HCC) Phase II: Dose Expansion: To assess the antitumor activity of BC3402 in combination with durvalumab in subjects with advanced HCC.
Timeline
- Start
- 2023-10
- Primary completion
- 2024-08
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC3402 | Monoclonal antibody | — | Intravenous |
| Background | Durvalumab | Monoclonal antibody | — | Intravenous |